Gland Pharma Ltd
Company Profile
Business description
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. The group is also involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.
Contact
Plot No. 11 and 84, TSIIC Phase: IV
Pashamylaram (V), Patancheru (M)
Sangareddy District
HyderabadTG502307
INDT: +91 8455699999
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2025
Employees
4,217
Stocks News & Analysis
stocks
What we think of the 3 big winners of the ASX 100
stocks
Chart of the week: Where do our analysts see value?
stocks
Attractive ASX opportunity with high yield
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,550.30 | 36.60 | -0.43% |
| CAC 40 | 7,409.57 | 11.37 | -0.15% |
| DAX 40 | 20,405.92 | 20.35 | -0.10% |
| Dow JONES (US) | 43,828.06 | 86.06 | -0.20% |
| FTSE 100 | 8,300.33 | 11.43 | -0.14% |
| HKSE | 19,971.24 | 425.81 | -2.09% |
| NASDAQ | 19,926.72 | 23.88 | 0.12% |
| Nikkei 225 | 39,470.44 | 378.70 | -0.95% |
| NZX 50 Index | 12,754.26 | 61.54 | 0.48% |
| S&P 500 | 6,051.09 | 0.16 | -0.00% |
| S&P/ASX 200 | 8,296.00 | 34.30 | -0.41% |
| SSE Composite Index | 3,391.88 | 69.62 | -2.01% |